SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Vaccinex, Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Vaccinex, Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 136,539 shares of Vaccinex, Inc. common stock.
• This ownership represents 4.99% of Vaccinex, Inc.'s outstanding common stock.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment position.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen and the managing member of Armistice Capital, is also deemed to beneficially own these shares.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Vaccinex, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's operational or financial performance. It simply reports a passive stake.

Positives

• The disclosure of a significant institutional investor, Armistice Capital, holding a nearly 5% stake, may signal confidence in Vaccinex, Inc. from a notable investment firm.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests that the investor is not seeking to influence or control the company, which can be viewed favorably by current management and other shareholders.

Negatives

• The filing itself does not contain negative information about Vaccinex, Inc.'s operational performance or financial outlook, as it is solely a disclosure of ownership.

Risks

• The document is a beneficial ownership disclosure and does not detail specific risks related to Vaccinex, Inc.'s business operations, financial health, or future prospects.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Vaccinex, Inc.'s future performance or strategic outlook.

Industry Context

This Schedule 13G filing is a standard regulatory disclosure of a significant passive investment. It does not provide insights into broader industry trends or competitive landscape, focusing solely on the ownership stake of Armistice Capital and Steven Boyd in Vaccinex, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a passive stake may be viewed positively, potentially indicating institutional confidence and liquidity for the stock.

Key Dates

Keywords

VACCINEX INC, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment, SEC Filing